Breztri Aerosphere (budesonide, formoterol fumarate, glycopyrrolate)

Where it stands

Breztri Aerosphere (budesonide, formoterol fumarate, glycopyrrolate), a metered aerosol from AstraZeneca AB, is recorded as approved by the FDA on 2026-10-08 under NDA220290. The official milestone describes the action as an approval in the category "new formulation or manufacturer".

The records do not give the therapeutic area or the approved indication, so this analysis cannot say which patient population the label covers. They also do not say what changed in the formulation or manufacturing, or whether the change is to the product's composition, its presentation or its manufacturing site.

Regulatory pathway and designations

The only designation recorded is "New formulation or manufacturer". This is a classification of the FDA action. It is not an expedited-program designation such as priority review or breakthrough therapy, and no such designations appear in the records. The records show no orphan status, no PDUFA goal date and no advisory committee activity.

The application is an NDA (NDA220290), which is the US pathway for a new drug application. The records give no CHMP opinion date, which is expected because the region is the US and the CHMP is the EU's scientific committee. The EU does not drive this action.

The records list EU-authorised products containing the same substances: Trixeo Aerosphere, Riltrava Aerosphere, Jorveza, Kinpeygo, GoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) and DuoResp Spiromax. The list appears to match on individual active substances, so these products differ in composition, dosage form and presumably indication. They should not be read as direct equivalents of the US product, and the records do not say how each relates to Breztri Aerosphere.

Safety and pharmacovigilance

The records contain no safety data, label warnings, risk management commitments or postmarketing requirements for this action, so no assessment of the product's safety profile can be made from them.

As a general point, an approved US product remains subject to routine postmarketing safety reporting. Where a formulation or manufacturing change is involved, reviewers would look at whether the label or quality controls need updating. Whether that applies here cannot be determined from the records.

What to watch

The first step is to retrieve the FDA approval letter and the updated labeling for NDA220290. These should show the approved indication, the exact nature of the formulation or manufacturer change, and any new postmarketing requirements.

Professionals should also check whether the change affects the product's presentation, such as device or propellant, or its supply, since the records are silent on both. Anyone comparing the US product with the EU-authorised products should do so against each product's own label, because the records give no basis for treating them as interchangeable.